Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 2 distinct examiners, providing a variety of examiner perspectives for the company's current filings. Both actions are located within 1 distinct art unit, indicating that the company's patent efforts are concentrated in a specific area of biological or pharmaceutical science. This concentration in 1 distinct art unit suggests a deep but narrow technical focus for the current portfolio.
The busiest examiner, YOH, JULIUS FRANCIS, is responsible for 1 pending office action, which is exactly 1 of the 2 pending office actions in the portfolio. The use of 2 distinct examiners within 1 distinct art unit suggests that while the technical field is narrow, the prosecution is not dependent on a single individual. This structure allows for a more diversified examination experience even within a single specialized unit of the patent office. Practitioners should be prepared to handle different examiner styles from YOH, JULIUS FRANCIS and the other assigned examiner while maintaining a consistent technical argument.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOH, JULIUS FRANCIS | 1 | 66.7% | +0.0% |
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17790438 | POLYPEPTIDE ENCODED BY EB VIRUS BNLF2B GENE AND USE THEREOF IN DETECTION | ZOU, NIANXIANG | 6d |
| 18697740 | MICROFLUIDIC CHIP AND MICROFLUIDIC CHIP DETECTION SYSTEM | YOH, JULIUS FRANCIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17790438 | POLYPEPTIDE ENCODED BY EB VIRUS BNLF2B GENE AND USE THEREOF IN DETECTION | ZOU, NIANXIANG | 6d |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18697740 | MICROFLUIDIC CHIP AND MICROFLUIDIC CHIP DETECTION SYSTEM | YOH, JULIUS FRANCIS | — | §102§103§112 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 17790438 | POLYPEPTIDE ENCODED BY EB VIRUS BNLF2B GENE AND USE THEREOF IN DETECTION | ZOU, NIANXIANG | 1671 | §103§112 | Non-Final OA | 6d | Pending | Jun 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial